Skip to main content

A Hodgkin Lymphoma trial - HD11

Comparing a combination of new agents to standard treatment for Hodgkin lymphoma patients who relapsed or did not respond to prior treatment
Disease Site
Hematologic Clinical Trials
Trial Code
HD.11 ǀ NCT05180097
Trial Status
Open to patient enrollment

What is the purpose of this study?

The purpose of this study is to see the effects on you and your lymphoma of a new drug combination compared to other drugs that are currently used in standard treatment.

Why is this study important?

The two new drugs being studied are a new therapy being developed for the treatment of Hodgkin Lymphoma that didn’t respond to or returned after earlier treatment. Laboratory tests show that the new drugs may help slow the growth of Hodgkin Lymphoma. The new drugs have been studied in a few people and seem promising, but it is not clear if they can offer better results than standard treatment.

Who can participate in this study?

This trial is for:

  • Adults with Hodgkin Lymphoma that came back after their first line of treatment
  • People who are relatively healthy but have disease that can be measured by doctors
  • People that will answer questions about their health and life quality
  • People who can come back for more visits for treatments and examinations

This trial is not for:

  • People who already got a second treatment after their cancer came back
  • People with a history of disease in their brain or spine, or in their heart in the 6 months before joining the study
  • People with a compromised immune system or autoimmune disease
  • People who are pregnant, lactating or not willing to use birth control
  • People who are having or have had another anti-cancer treatment in the 4 weeks before joining the study
What are the risks?
  • If you choose to take part in this study, there is a risk that the new drugs may not be as good as the standard treatment. There is also a risk of side effects from the new drugs. Some of the most common side effects that the study doctors know about are: 
    • diarrhea 
    • nausea 
    • tiredness 
    • numbness, tingling or pain of the arms and legs 
    • itching or rash
  • You will find more details of risks and possible side effects from both treatment groups in the Informed Consent document.
What can I expect?
  • If you choose to take part in this study, you will be randomly placed in one of two groups and you will receive either the new drugs or other drugs that are commonly used to treat this disease.
  • In this study, you will also be asked to complete a few questionnaires at different times, to understand your Quality of Life.

How can I find out more or join the study?

Talk to your cancer doctor if you are considering joining this study. You can share summaries like this with them and ask if they think joining the trial may be a good option for you.

Before you join this study, you will be asked to review an Informed Consent document which will tell you more about why the research is being done and your role as a participant. You will have an opportunity to discuss anything that is not clear and ask any questions you have.

Joining this study is entirely up to you and you can decide to leave at any time without giving a reason. Your decision to join or leave the trial will not affect your standard medical care.

The HD.11 study is currently enrolling patients at cancer centres in Canada. For a full list of participating cancer centres please visit https://clinicaltrials.gov/study/NCT05180097?term=NCT05180097&rank=1 or go to www.clinicaltrials.gov and search using the code NCT05180097.

Use this trial information for your conversation with your health care team

Participating centres
  • Dr. H. Bliss Murphy Cancer Centre - St. John's, NF, A1B 3V6 - Contact: Dr. Jacqueline Costello
  • QEII Health Sciences Centre Capital District Health Authority - Halifax, NS, B3H 1V7 - Contact: Dr. Mary-Margaret Keating
  • CIUSSS de l'Estrie - Centre hospitalier universitaire de Sherbrooke - Sherbrooke, QC, J1H 5N4 - Contact: Dr. Stephanie Desilets
  • The Jewish General Hospital - Montreal, QC, H3T 1E2 - Contact: Dr. Nathalie Johnson
  • The Research Institute of the McGill University Health Centre - Montreal, QC, H4A 3J1 - Contact: Dr. Kelly Davison
  • Ottawa Hospital Research Institute - Ottawa, ON, K1H 8L6 - Contact: Dr. Isabelle Bence-Bruckler
  • Juravinski Cancer Centre at Hamilton Health Sciences - Hamilton, ON, L8V 5C2 - Contact: Dr. Amaris Balitsky
  • University Health Network Princess Margaret Cancer Centre - Toronto, ON, M5G 2M9 - Contact: Dr. John Kuruvilla
  • London Regional Cancer Program - London, ON, N6A 5W9 - Contact: Dr. Joy Elise Mangel
  • Allan Blair Cancer Centre - Regina, SK, S4T 7T1 - Contact: Dr. Muhammad Salim
  • Tom Baker Cancer Centre - Calgary, AB, T2N 4N2 - Contact: Dr. Sarah Perry
  • BCCA - Vancouver - Vancouver, BC, V5Z 4E6 - Contact: Dr. Kerry J. Savage